Comparing Darunavir vs Symtuza
Darunavir | Symtuza (cobicistat / darunavir / emtricitabine / tenofovir alafenamide) |
|
---|
Darunavir | Symtuza (cobicistat / darunavir / emtricitabine / tenofovir alafenamide) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for HIV Infection. Darunavir may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for HIV Infection. Symtuza may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Darunavir | More about Symtuza (cobicistat / darunavir / emtricitabine / tenofovir alafenamide) | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Darunavir has an average rating of 7.6 out of 10 from a total of 5 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 20% reported a negative effect. |
Symtuza has an average rating of 8.3 out of 10 from a total of 9 ratings on Drugs.com. 89% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Darunavir side effects |
View all Symtuza side effects |
||||||||||||||||
Drug Class | |||||||||||||||||
Generic Availability | |||||||||||||||||
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Darunavir prices |
View all Symtuza prices |
||||||||||||||||
Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Prezista |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
15 hours |
180 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 531 drugs are known to interact with Darunavir:
|
A total of 772 drugs are known to interact with Symtuza:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
June 23, 2006 |
July 17, 2018 |
||||||||||||||||
WADA Class View classifications | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient Resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Dovato
Dovato is a complete HIV-1 treatment regimen in one tablet that may be used in adults and children ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Apretude
Apretude is used to prevent HIV (HIV PrEP) in adults and adolescents weighing at least 77 pounds ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.